Please enable Javascript
An official publication of
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Cecilia Brown
Associate Editor
Cecilia Brown is an Associate Editor for Blood Cancers Today.
Articles by Cecilia Brown
Dr. Coombs on Second Generation BTK Inhibitors for CLL
Catherine Coombs, MD
Chronic Lymphocytic Leukemia
|
September 25, 2024
The newer agents have distinguished themselves especially by having safety profiles superior to ibrutinib.
View More
Dr. Bose on JAK Inhibitor Optimization, Trial Updates in Myelofibrosis
Prithviraj Bose, MD
Myelofibrosis
|
September 25, 2024
An expert on myelofibrosis comments on promising results from current trials and on the need for useful clinical biomarkers.
View More
Axi-Cel Leads to ‘Continued Durable Responses’ in Patients With Indolent B-Cell Lymphoma
Cecilia Brown
Indolent B-Cell Lymphoma
|
June 26, 2024
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Read More
Get to Know… Irene Ghobrial, MD
Cecilia Brown
Print
|
January 3, 2024
Dr. Ghobrial discusses how she entered the field of smoldering myeloma, the racial gap in myeloma research, and more.
Read More
Get to Know... Sarah Tasian, MD
Cecilia Brown
Print
|
November 13, 2023
Dr. Tasian discusses the path that took her to the best job in the world, silver linings along the way, and more.
Read More
Multidisciplinary Study Evaluates Prevalence of Hematologic Malignancies in Familial Platelet Disorder
Cecilia Brown
Myelodysplastic Syndromes
|
October 25, 2023
The study enrolled 214 participants, including 111 patients with 39 different RUNX1 variants from 45 unrelated families.
Read More
Dr. Garcia-Manero on the Meaning of MDS Awareness Day
Guillermo Garcia-Manero, MD
Myelodysplastic Syndromes
|
February 8, 2024
Dr. Garcia-Manero said he hopes to find “better treatments” and even “one day a cure for this condition.”
View More
Does Autoimmune Disease Impact Outcomes in MDS?
Cecilia Brown
Myelodysplastic Syndromes
|
October 24, 2023
Researchers found that 16% of the patients analyzed had pre-existing autoimmune disease.
Read More
Dr. Badar on the Prognostic Heterogeneity of U2AF1 Pathogenic Variants
Talha Badar, MBBS, MD
Myelodysplastic Syndromes
|
October 23, 2023
Across the entire study population, the two most frequent U2AF1 variants were S34F (n=97) and Q157P (n=46).
View More
IV Immunoglobulin Linked with Reduced Infections in Patients Receiving Anti-BCMA Bispecific
Cecilia Brown
Myeloma
|
October 16, 2023
The rate of grade 3-5 infections was 90% lower in MM patients receiving IV immunoglobulin than during the observation period.
Read More
Genomic Analysis Reveals Genetically Distinct Subgroups of Follicular Lymphoma
Cecilia Brown
Indolent B-Cell Lymphoma
|
October 13, 2023
Researchers used a classification approach derived from machine learning to stratify patients into two subgroups.
Read More
Phase II ROSEWOOD Study Shows Doublet Has ‘Meaningful Activity’ in Follicular Lymphoma
Cecilia Brown
Indolent B-Cell Lymphoma
|
October 13, 2023
The combination was previously “found to be well tolerated with an early signal of efficacy in a phase Ib study.”
Read More
EC Grants Conditional Marketing Authorization to Epcoritamab for Relapsed, Refractory DLBCL
Cecilia Brown
Aggressive B-Cell Lymphoma
|
October 18, 2023
The subcutaneous T-cell engaging bispecific antibody is now approved for the treatment of this patient population in the EU.
Read More
Phase III Study Evaluates Efficacy, Safety of Guadecitabine in AML
Cecilia Brown
Acute Myeloid Leukemia
|
October 11, 2023
The study included 815 patients with AML who were “unfit to receive intensive induction chemotherapy."
Read More
How Do Mutations, Age Impact AML Outcomes?
Cecilia Brown
Acute Myeloid Leukemia
|
October 11, 2023
Mutations in IDH were “strongly correlated with increased age,” according to the study’s authors.
Read More
Dual Targeting of CD22, CD19 with CAR-T Shows Efficacy in Relapsed, Refractory ALL
Cecilia Brown
Acute Lymphoblastic Leukemia
|
October 3, 2023
The pooled ORR was 97% and the pooled complete remission rate was 93% in patients with ALL.
Read More
Study Evaluates Adding Blinatumomab to Chemotherapy in Young Patients with B-ALL
Cecilia Brown
Acute Lymphoblastic Leukemia
|
October 2, 2023
The study included 255 patients aged one to 30 years with low-risk first-relapse B-ALL.
Read More
Get to Know … Jerald Radich, MD
Cecilia Brown
Chronic Myeloid Leukemia
|
October 11, 2023
Dr. Radich reflects on lessons in cowboy medicine, the genetics of luck, and a serendipitous meeting.
Read More
How Prevalent Are Financial, Time Toxicity in Patients with Multiple Myeloma?
Cecilia Brown
Meeting News
|
October 2, 2023
Researchers conducted a cross-sectional survey of patients with multiple myeloma to address the question.
Read More
SOHO Keating Awardee Dr. Cortes Speaks on the Honor
Jorge Cortes, MD
Video Insights
|
September 29, 2023
The award was created in honor of Michael J. Keating, MD, a founding member and past president of SOHO.
View More
Load More